TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35963416

Group type: EXPERIMENTAL
Intervention: R. damascena and brown sugar syrup (0.1 g R. damascena petals mixed with 0.85 g brown sugar per 1 mL)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Polyethylene Glycol (PEG)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: R. damascena and brown sugar syrup
Number of subjects: 100
Study: 34135392

Group type: EXPERIMENTAL
Intervention: tDCS with music listening (tDCS + Music)
Number of subjects: 14

Group type: COMPARATOR
Intervention: tDCS in silence (tDCS-only)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Sham-tDCS with music listening (Sham + Music)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: tDCS + Music
Number of subjects: 14
Study: 36151947

Group type: EXPERIMENTAL
Intervention: Needle flexor tendon tenotomy treatment
Number of subjects: 95

Group type: COMPARATOR
Intervention: Standard nonsurgical treatment alone
Number of subjects: 95
Study: 32493720

Group type: EXPERIMENTAL
Intervention: HIV Env subunit vaccine
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 35056358

Group type: EXPERIMENTAL
Intervention: Reciproc Blue
Number of subjects: 51

Group type: COMPARATOR
Intervention: Protaper NEXT
Number of subjects: 51
Study: 36115523

Group type: EXPERIMENTAL
Intervention: Deucravacitinib 6 mg QD
Number of subjects: 1020

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1020

Group type: COMPARATOR
Intervention: Apremilast 30 mg BID
Number of subjects: 1020
Study: 34416381

Group type: EXPERIMENTAL
Intervention: Instrumentation at 0.0 measurement
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Instrumentation at 0.0 measurement + PDT
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Instrumentation 1mm beyond 0.0 measurement
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Instrumentation 1mm beyond 0.0 measurement + PDT
Number of subjects: 40
Study: 32713104

Group type: EXPERIMENTAL
Intervention: High-dose dual therapy (HDDT) with rabeprazole 20 mg q.i.d. and amoxicillin 1 g q.i.d. for 14 days
Number of subjects: 191

Group type: COMPARATOR
Intervention: Standard triple therapy (STT) with rabeprazole 20 mg b.i.d., amoxicillin 1 g b.i.d., and clarithromycin 500 mg b.i.d. for 14 days
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: High-dose dual therapy (HDDT)
Number of subjects: 191

Group type: COMPARATOR
Intervention: Standard triple therapy (STT)
Number of subjects: 191
Study: 35270527

Group type: EXPERIMENTAL
Intervention: Integrated Workplace Violence Prevention and Management Training Program
Number of subjects: 75
Study: 34724899

Group type: EXPERIMENTAL
Intervention: Graded walking protocol with biweekly phone calls for compliance monitoring
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (no intervention or biweekly monitoring)
Number of subjects: 45
Study: 32153209

Group type: EXPERIMENTAL
Intervention: Patient Health Questionnaire item 9 response of 2 or 3
Number of subjects: 2928927

Group type: EXPERIMENTAL
Intervention: Patient Health Questionnaire item 9 response of 3
Number of subjects: 2928927

Group type: EXPERIMENTAL
Intervention: Suicide risk score of 90th percentile or higher
Number of subjects: 2928927

Group type: EXPERIMENTAL
Intervention: Suicide risk score of 95th percentile or higher
Number of subjects: 2928927

Group type: EXPERIMENTAL
Intervention: Suicide risk score of 99th percentile or higher
Number of subjects: 2928927
Study: 34936109

Group type: EXPERIMENTAL
Intervention: Anterior palatoplasty and expansion sphincter pharyngoplasty (APwESP)
Number of subjects: 91
Study: 32246662

Group type: EXPERIMENTAL
Intervention: Topical nitroglycerin ointment
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: Topical diltiazem ointment
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: Surgical lateral internal sphincterotomy
Number of subjects: 550
Study: 35020928

Group type: EXPERIMENTAL
Intervention: Viral features alone (CXR)
Number of subjects: 1321

Group type: COMPARATOR
Intervention: Normal CXRs
Number of subjects: 1321

Group type: EXPERIMENTAL
Intervention: Concurrent viral features and radiographic pneumonia
Number of subjects: 1321

Group type: COMPARATOR
Intervention: Radiographic pneumonia alone
Number of subjects: 1321
Study: 34631651

Group type: EXPERIMENTAL
Intervention: Hydroponic planting integrated with health promotion activities (two times per week for 8 months)
Number of subjects: 553

Group type: EXPERIMENTAL
Intervention: Health promotion activities (one time per week for 6 weeks)
Number of subjects: 553

Group type: EXPERIMENTAL
Intervention: Hydroponic planting integrated with health promotion activities
Number of subjects: 553

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 553
Study: 34747975

Group type: EXPERIMENTAL
Intervention: Noncontrast CT
Number of subjects: 1604

Group type: EXPERIMENTAL
Intervention: CTP
Number of subjects: 1604

Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 1604
Study: 33289822

Group type: EXPERIMENTAL
Intervention: Co-trimoxazole (960 mg orally twice daily)
Number of subjects: 342

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 342
Study: 34546408

Group type: EXPERIMENTAL
Intervention: TMT (a newly developed five-session couple-focused intervention)
Number of subjects: 60

Group type: COMPARATOR
Intervention: TAU (usual care)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both TMT and TAU
Number of subjects: 60
Study: 34228547

Group type: EXPERIMENTAL
Intervention: Systemic antibiotic agents
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Doxycycline-rifampicin
Number of subjects: 224

Group type: COMPARATOR
Intervention: 7-day treatment
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 224

Group type: COMPARATOR
Intervention: Immunocompromised status
Number of subjects: 224
Study: 32032673

Group type: EXPERIMENTAL
Intervention: Vegetarian eaters
Number of subjects: 0

Group type: COMPARATOR
Intervention: Omnivorous group
Number of subjects: 0
Study: 33400412

Group type: EXPERIMENTAL
Intervention: VP-102 (0.7% w/v cantharidin) applied topically every 21 days for a maximum of 4 treatments.
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: VP-102 (0.7% w/v cantharidin)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Systemic exposure group (VP-102)
Number of subjects: 33
Study: 33120757

Group type: EXPERIMENTAL
Intervention: Yishentongluo decoction (YSTL)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Levocarnitine oral solution
Number of subjects: 160
Study: 34445938

Group type: EXPERIMENTAL
Intervention: Supportive techniques
Number of subjects: 86
Study: 33767255

Group type: EXPERIMENTAL
Intervention: Shallow squat training (SS group)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Deep squat training (DS group)
Number of subjects: 16
Study: 32234700

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I) app used for 6 weeks
Number of subjects: 312

Group type: COMPARATOR
Intervention: Patient Education (PE) through the app
Number of subjects: 312
Study: 35020023

Group type: EXPERIMENTAL
Intervention: Epsilon-aminocaproic acid (EACA) 20 ml of 5% solution
Number of subjects: 85

Group type: COMPARATOR
Intervention: Normal saline (control) 20 ml
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Epsilon-aminocaproic acid (EACA)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 85
Study: 33757437

Group type: EXPERIMENTAL
Intervention: Cinacalcet alongside standard therapy
Number of subjects: 36

Group type: COMPARATOR
Intervention: Standard therapy alone
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Combined groups
Number of subjects: 36
Study: 33277579

Group type: EXPERIMENTAL
Intervention: Micro-intervention (15 min)
Number of subjects: 2
Study: 34415079

Group type: EXPERIMENTAL
Intervention: Hearing Aid (HA) use with baseline accommodations for 12 weeks
Number of subjects: 34

Group type: COMPARATOR
Intervention: Baseline accommodations only for 12 weeks
Number of subjects: 34
Study: 33462096

Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Nadroparin
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 198
Study: 32270476

Group type: EXPERIMENTAL
Intervention: Rinse-free hand washing
Number of subjects: 30747
Study: 33534264

Group type: EXPERIMENTAL
Intervention: Physostigmine (0.02 mg/kg bolus followed by 0.01 mg/kg/hour for 24 hours)
Number of subjects: 261

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Physostigmine
Number of subjects: 261
Study: 34320232

Group type: EXPERIMENTAL
Intervention: Standardized clinical trials for Wilson disease
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pooling of data from standardized clinical trials
Number of subjects: 0
Study: 32535711

Group type: EXPERIMENTAL
Intervention: Gemcitabine (1000 mg/m2) plus Oxaliplatin (100 mg/m2) every 2 weeks
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus Oxaliplatin (GEMOX)
Number of subjects: 45
Study: 35490601

Group type: EXPERIMENTAL
Intervention: eLearning module (n=85)
Number of subjects: 271

Group type: COMPARATOR
Intervention: Face-to-face teaching (n=186)
Number of subjects: 271
Study: 33190991

Group type: EXPERIMENTAL
Intervention: BCM equation for predicting appendicular skeletal muscle mass (ASM)
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: BCM equation for predicting ASM
Number of subjects: 263
Study: 33590739

Group type: EXPERIMENTAL
Intervention: Therapist-led care pathway including group education, a splint, and home exercises
Number of subjects: 105

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 105
Study: 33621921

Group type: EXPERIMENTAL
Intervention: Parent intervention
Number of subjects: 2922

Group type: EXPERIMENTAL
Intervention: Student intervention
Number of subjects: 2922

Group type: EXPERIMENTAL
Intervention: Parent + Student intervention
Number of subjects: 2922

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 2922
Study: 32033815

Group type: EXPERIMENTAL
Intervention: Sublobar resection (SLR)
Number of subjects: 53973

Group type: COMPARATOR
Intervention: Stereotactic body radiation therapy (SBRT)
Number of subjects: 53973

Group type: COMPARATOR
Intervention: Ablation
Number of subjects: 53973
Study: 35653338

Group type: EXPERIMENTAL
Intervention: Aspirin 81 mg/day
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: Aspirin 325 mg/day
Number of subjects: 523

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 523
Study: 32058451

Group type: EXPERIMENTAL
Intervention: True dry needling
Number of subjects: 62

Group type: COMPARATOR
Intervention: Sham dry needling
Number of subjects: 62
Study: 32780676

Group type: EXPERIMENTAL
Intervention: HIV self-testing
Number of subjects: 24
Study: 35279069

Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT) group
Number of subjects: 508

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 508
Study: 34479057

Group type: EXPERIMENTAL
Intervention: SARA (Scale for the Assessment and Rating of Ataxia)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Patient Global Impression of Change scale
Number of subjects: 20
Study: 32410683

Group type: EXPERIMENTAL
Intervention: Ulinastatin
Number of subjects: 426

Group type: COMPARATOR
Intervention: Control (Normal Saline)
Number of subjects: 426
Study: 33349043

Group type: EXPERIMENTAL
Intervention: Standard active training instruction
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo-related instruction
Number of subjects: 33
Study: 32723107

Group type: EXPERIMENTAL
Intervention: Nomogram to predict 14-day probability of poor outcome
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Multivariable analyses
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Nomogram
Number of subjects: 279
Study: 35447274

Group type: EXPERIMENTAL
Intervention: Passive range of motion (PROM) exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study: 32720608

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (1g IV every 12 hours for at least 7 days)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Levofloxacin (750 mg IV daily for at least 7 days)
Number of subjects: 59
Study: 32320006

Group type: EXPERIMENTAL
Intervention: Nicotinamide riboside (NR) 1000 mg/d for 6 weeks
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 35962482

Group type: EXPERIMENTAL
Intervention: Mediterranean Diet (MD)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Low-Fat Diet (LFD)
Number of subjects: 23
Study: 33606004

Group type: EXPERIMENTAL
Intervention: D-RVd (daratumumab plus lenalidomide/bortezomib/dexamethasone)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: D-RVd (daratumumab plus lenalidomide/bortezomib/dexamethasone) followed by D-R (daratumumab plus lenalidomide) maintenance
Number of subjects: 16
Study: 32698144

Group type: EXPERIMENTAL
Intervention: Genetically instrumented TSH (approximately 0.8 mIU/L)
Number of subjects: 451025
Study: 36170970

Group type: EXPERIMENTAL
Intervention: Fasted (FAST)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Fed (FED)
Number of subjects: 16
Study: 32703721

Group type: EXPERIMENTAL
Intervention: Ketogenic diet (KD)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study: 35701760

Group type: EXPERIMENTAL
Intervention: Family meal
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: School meal
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Friend meal
Number of subjects: 32
Study: 35918690

Group type: EXPERIMENTAL
Intervention: Telerehabilitation interventions
Number of subjects: 80
Study: 33565893

Group type: EXPERIMENTAL
Intervention: Esketamine nasal spray plus oral antidepressant (ESK + oral AD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral antidepressant plus nasal placebo (oral AD + PBO)
Number of subjects: 0
Study: 32646424

Group type: EXPERIMENTAL
Intervention: Tiotropium 18 μg
Number of subjects: 5652

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5652
Study: 35954846

Group type: EXPERIMENTAL
Intervention: Resource-strengthening training for parents (Res@t-P)
Number of subjects: 43
Study: 33823606

Group type: EXPERIMENTAL
Intervention: Dual-therapy sirolimus-eluting and CD34+ antibody-coated Combo stent (DTS)
Number of subjects: 3146

Group type: COMPARATOR
Intervention: Sirolimus-eluting Orsiro stent (SES)
Number of subjects: 3146

Group type: EXPERIMENTAL
Intervention: Both DTS and SES
Number of subjects: 3146
Study: 36178946

Group type: EXPERIMENTAL
Intervention: Real US-guided dry needling with exercise therapy (G1)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo US-guided dry needling with exercise therapy (G2)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Exercise therapy solely (G3)
Number of subjects: 84
Study: 33694001

Group type: EXPERIMENTAL
Intervention: 90% calf starter concentrate (CSC) + 10% chopped wheat straw (WS) offered from day 21 of age to weaning (WS21)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 90% calf starter concentrate (CSC) + 10% chopped wheat straw (WS) offered from day 3 of age to weaning (WS3)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 90% calf starter concentrate (CSC) + 10% chopped wheat straw (WS) offered from day 40 of age to weaning (WS40)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control starter without any wheat straw (WS) inclusion until weaning (WS0)
Number of subjects: 40
Study: 32169925

Group type: EXPERIMENTAL
Intervention: Hybrid closed-loop (CL) insulin delivery for 24 months
Number of subjects: 96

Group type: COMPARATOR
Intervention: Standard multiple daily injections (MDI) therapy for 24 months
Number of subjects: 96
Study: 36450940

Group type: EXPERIMENTAL
Intervention: 200-mg testosterone enanthate/wk (TEST)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 50
Study: 32881572

Group type: EXPERIMENTAL
Intervention: Psychosocial intervention (details not specified)
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: 7-item scale (abbreviated PTGI and BFS)
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: 16-item scale (abbreviated PTGI and BFS)
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: 11-item scale (abbreviated PTGI and BFS)
Number of subjects: 209
Study: 35677761

Group type: EXPERIMENTAL
Intervention: PA + SB group (dyadic approach)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: PA + SB + sleep group (integrated approach)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 150
Study: 33241429

Group type: EXPERIMENTAL
Intervention: Self-guided learning using a video-based self-assessment (SA)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group watching an LH video demonstration
Number of subjects: 24
Study: 35134151

Group type: EXPERIMENTAL
Intervention: Cryoballoon ablation (CBA)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 101
Study: 34342246

Group type: EXPERIMENTAL
Intervention: 1% Trypan blue (TB) applied to one eye before capsulorhexis
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (no TB applied)
Number of subjects: 46
Study: 35713950

Group type: EXPERIMENTAL
Intervention: Progesterone 200 mg daily
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 33428364

Group type: EXPERIMENTAL
Intervention: Decompression, decompression with fusion, and decompression with stabilization
Number of subjects: 70

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 70
Study: 33619014

Group type: EXPERIMENTAL
Intervention: Withdrawal of nebulised dornase alfa for one month
Number of subjects: 28

Group type: COMPARATOR
Intervention: Standard care (no withdrawal of dornase alfa)
Number of subjects: 28
Study: 32238338

Group type: EXPERIMENTAL
Intervention: Integration of web and text message platforms (on)
Number of subjects: 864

Group type: EXPERIMENTAL
Intervention: Dynamic tailoring of intervention content based on user engagement (on)
Number of subjects: 864

Group type: EXPERIMENTAL
Intervention: All experimental factors active (personalization, integration, dynamic tailoring, message intensity)
Number of subjects: 864

Group type: EXPERIMENTAL
Intervention: Build Support System
Number of subjects: 864

Group type: EXPERIMENTAL
Intervention: Choose Quit Smoking Aid
Number of subjects: 864

Group type: EXPERIMENTAL
Intervention: Track Smoking Triggers
Number of subjects: 864

Group type: EXPERIMENTAL
Intervention: Overall feature utilization
Number of subjects: 864

Group type: EXPERIMENTAL
Intervention: Time on site
Number of subjects: 864
Study: 34435933

Group type: EXPERIMENTAL
Intervention: Two doses of tetravalent measles-mumps-rubella-varicella vaccine (V2 group)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: One dose trivalent measles-mumps-rubella (MMR) vaccine and one dose of varicella vaccine (V1 group)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Two doses of MMR vaccine (V0 group, control)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Both V2 and V1 groups
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 1000
Study: 32686972

Group type: EXPERIMENTAL
Intervention: Lifestyle‐promoting text messages sent every week for six months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 60
Study: 36104819

Group type: EXPERIMENTAL
Intervention: Parent and Public Involvement (PPI) process in trial planning
Number of subjects: 675

Group type: EXPERIMENTAL
Intervention: PPI impact on study design
Number of subjects: 675
Study: 34078421

Group type: EXPERIMENTAL
Intervention: gelatine‐crystalloid regime (Gelaspan® 4% and Sterofundin® ISO, B. Braun Melsungen AG, in a 1:1 ratio)
Number of subjects: 608

Group type: COMPARATOR
Intervention: pure crystalloid regime (Sterofundin® ISO)
Number of subjects: 608
Study: 36149254

Group type: EXPERIMENTAL
Intervention: Intravenous thrombolysis (IVT)
Number of subjects: 13901

Group type: COMPARATOR
Intervention: Other medical management
Number of subjects: 13901
Study: 33579345

Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES) combined with branched-chain amino acids (BCAA)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Neuromuscular electrical stimulation (NMES) alone
Number of subjects: 50
Study: 33827700

Group type: EXPERIMENTAL
Intervention: Calcitriol treatment (0.25 mcg/day for 4 months)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Calcitriol treatment (0.25 mcg/day for 4 months) in patients with Ff genotype
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study: 34007434

Group type: EXPERIMENTAL
Intervention: Operating room nursing intervention combined with traditional treatment methods
Number of subjects: 80

Group type: COMPARATOR
Intervention: Traditional nursing combined with traditional treatment
Number of subjects: 80
Study: 32003520

Group type: EXPERIMENTAL
Intervention: Sleep Coach intervention
Number of subjects: 39
Study: 34463805

Group type: EXPERIMENTAL
Intervention: Oral analgesia group (spinal fentanyl followed by oral tramadol, paracetamol, and diclofenac every 6 hours for 48 hours)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Spinal morphine group (spinal morphine followed by oral tramadol, paracetamol, and diclofenac)
Number of subjects: 200
Study: 33020005

Group type: EXPERIMENTAL
Intervention: 6 educational sessions, parent feedback via the Communication Assessment Tool (CAT), monthly communication tips
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study: 35409693

Group type: EXPERIMENTAL
Intervention: BCLT program (n = 47)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control group (n = 46)
Number of subjects: 93
Study: 32048017

Group type: EXPERIMENTAL
Intervention: UHMWPE‐XE
Number of subjects: 94

Group type: COMPARATOR
Intervention: UHMWPE‐X
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 94
Study: 34856706

Group type: EXPERIMENTAL
Intervention: SNK01 plus pembrolizumab
Number of subjects: 18

Group type: COMPARATOR
Intervention: pembrolizumab monotherapy
Number of subjects: 18
Study: 33492879

Group type: EXPERIMENTAL
Intervention: Acupressure applied to the Neiguan (PC 6) acupuncture point
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study: 35286760

Group type: EXPERIMENTAL
Intervention: Belatacept-based immunosuppression (Tacrolimus, Belatacept, and prednisone until day 89 followed by Belatacept, Mycophenolate Mofetil, and prednisone)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control (Tacrolimus, Mycophenolate Mofetil, and prednisone)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Belatacept-based immunosuppression
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control
Number of subjects: 27